Tag Archives: San Francisco

Hot Investor Mandate 3: San Francisco-based Large Global Private Investment Firm Seeking Early-Stage Therapeutics and Commercial-Stage Devices Worldwide

10 May

A large PE/VC is investing in life science innovation through its $5B Growth and Rise funds. The firm is a leading global private investment firm with over $59 billion AUM, based in San Francisco, California. The investment size typically ranges from $20M to $50M in equity. The firm is agnostic to company location or stage.

The firm aims to invest in therapeutics, commercial stage medical devices, and opportunistically in other innovative life sciences spaces. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI San Francisco Innovation Challenge – Check Out the Winners

11 Jan

By Nono Hu, Director of Marketing, LSN

RESI San Francisco 2018 was the biggest Redefining Early Stage Investments event yet. In a highly competitive RESI Innovation Challenge we saw novel technologies represented from the therapeutics, medtech, diagnostics, and healthcare IT verticals – we know it was tough for RESI attendees to choose how to allocate their 5 RESI “investment” tokens! We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Place: CorInnova

With a $6 million lead investment from the UK-based Wellcome Trust ($26 billion in assets), CorInnova is developing an innovative minimally invasive cardiac assist device to treat heart failure. The collapsible soft robotic direct cardiac compression device, deployed minimally invasively into the pericardial space around the heart, does not touch the blood. The device should reduce hospital length of stay from 30 to 4 days and adverse events vs. LVADS by 40%. It will expand the eligible patient population 3 to 4X to an addressable market of up to $14 billion. CorInnova has a world-class team. First-in-human trials are anticipated to begin in 18 months. Three similar cardiac companies with only 10 patients’ data sold for $250 to $400 million in cash.

Boris Leschinsky, Vice President of Product Development,CorInnova | Dennis Ford, CEO, Life Science Nation | William Altman, CEO, CorInnova | Keith Svagerko, Vice President, Business Development, CorInnova

 

Second Place: ImmunoBiochem Corporation

ImmunoBiochem is a privately held biopharmaceutical company solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) – a promising class of biological anticancer therapeutics. ImmunoBiochem has identified a class of molecular targets that are secreted by cancer cells, but not healthy cells, and possess unique properties enabling the highly-selective delivery of toxic payloads to cancer cells, while leaving normal cells unharmed. ImmunoBiochem’s next-generation biologics aim to offer a superior safety profile and broad therapeutic window. Lead candidate, IMB-212, is aimed at a well-characterized cancer biomarker supported by a wealth of clinical data, and is being developed for Triple-Negative Breast Cancer (TNBC) – an aggressive disease for which no targeted biologics treatment options are available.

Dennis Ford, CEO, Life Science Nation | Anton Neschadim, CEO, ImmunoBiochem | Lucy Parkinson, Director of Investor Research, LSN

 

Third Place: Biorez

Biorez is an early-stage regenerative medicine company developing a bioresorbable scaffold for ACL reconstruction. Despite over 400,000 procedures each year, current surgical options are limited to autograft tissue, which requires a patient to sacrifice their own tendon, or allograft tissue, which is harvested from cadavers and has a higher failure rate. There is a large, unmet clinical need for a consistent, off-the-shelf device for ligament regeneration. The Biorez device provides the necessary strength to support physical activity, while its highly porous, proprietary structure facilitates a patient’s own cells to follow the scaffold and regenerate new functional tissue. The company is supported by early-stage VC investors, world-class scientific advisors, and a dedicated team to commercialize this exciting technology.

Dennis Ford, CEO, Life Science Nation | Kevin Rocco, CEO, Biorez | Lucy Parkinson, Director of Investor Research, LSN

Thank you to all who competed in the RESI JPM Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies. Welcome to join our upcoming RESI on MaRS event on April 10th, register now.

Meet The RESI San Francisco Innovation Challenge Finalists

21 Dec

By Chris Cummings, Senior Marketing Manager, LSN

Happy Holidays! With just under 3 weeks until the 4th annual RESI San Francisco, LSN is proud to announce this year’s crop of innovative new life science companies participating in the RESI Innovation Challenge.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants are vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

Previous Innovation Challenge participants have proven to be successful entrepreneurs; we have seen as many as 50% of companies in a Challenge receive funding within one year of the conference. Top competitors are able to find a balance between utilizing both the structure of RESI’s partnering system, and the ad-hoc nature of the Innovation Challenge.

On January 9th, RESI SF’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

Therapeutic

Medtech Device

Diagnostic

Healthcare IT

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

14 Dec

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital

WuXi AppTec Signs on as a RESI Title Sponsor for Boston, NYC and San Francisco Conferences

10 Aug

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-newLSN is pleased to announce WuXi AppTec will be a title sponsor to the RESI Conference Series in our upcoming Boston, NYC and San Francisco conferences. WuXi AppTec is a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform. WuXi AppTec joins RESI as a title sponsor along with JLABS, which currently has eight locations in innovation hotspots across North America and produces entrepreneurial programs and campaigns to seek out the best science. This pair of global early stage players will add another conduit to the early stage companies that come to RESI to find investor capital and strategic partnerships as they move forward in their product cycles.

The WuXi AppTec-LSN relationship has been growing over the years and WuXi AppTec has helped and been a contributor in our efforts with RESI content programing, panel participation, and creation of relationships with the scientist entrepreneurs and fundraising CEOs who are the main constituents of the RESI conference series.

RESI San Francisco Asia Pacific Investors Panel

26 Jan

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:

Key takeaway points from the panel:

  • Chinese investors are pushed to look overseas by the following forces: asset price, scarcity of high-quality products, and scarcity of exit in the public market. Many of them are seeking one or more of the following factors from US early stage companies: cutting-edge technologies, large sales potential in their domestic markets, and access to the US market.
  • The Chinese government’s new currency restriction has impacted some transactions and created uncertainty in the future. Dual currency funds (firms that manage domestic RMB and offshore USD funds) are less affected.
  • To engage a Chinese partner, it is key to identify a ‘China hook’ of your product. Large patient population is only one factor. Regulatory process, medical practice, and reimbursement should also be considered.
  • A good partnership can come in different forms: direct investment, licensing, joint venture, M&A, etc. Entrepreneurs should work with experienced investors to form a partnership that is most suitable for their product sector and stage.

RESI Innovators Shine in San Francisco – Winners Announced

12 Jan

Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison

Shaoyu 10*10The third RESI San Francisco Conference event, held on January 10th, saw 30 Innovation Challenge finalists competing for the votes of the largest RESI crowd to date.  With 1,000 attendees present, more votes were cast than in any Innovation Challenge to date. Biotech, medical device, diagnostic and digital health companies all competed in the exhibition-style challenge for the top prize.  Selected from over 100 applicants, the 30 finalists included many phenomenal startups.  Here, LSN would like to present the 3 winners.

First Place: Pathcore (Toronto, Canada)

pathcore-500t

Pathcore brings innovation to the crossroads of pathology and computation. By leveraging the power of digital computing and algorithm-based image analysis, digital pathology has the potential to transform healthcare. Pathology is essential to the diagnosis and treatment of cancer and other diseases, as well as the discovery and evaluation of new treatments. Hundreds of millions of dollars are spent on cancer research every year, and Pathcore is focused on providing the tools to accelerate that research and translate it into applied solutions. Pathcore is committed to pathologists and the patients they serve. Our software solutions are designed by pathologists, for pathologists, to enable them to work together, share their knowledge and expertise, and be more accurate, effective, and efficient.

Michael Quigley, VP of Market Research, Life Science Nation | Dan Hosseinzadeh, CEO, Pathcore | George Ayd Assistant Vice President, Medmarc | Stephane Langevin, CCO, Pathcore

Second Place: Myndblue (Cambridge, MA)

myndblue-500

MyndBlue is a digital health/ connected medical device that detects and monitors relapse/recurrence in Major Depressive Disorders and Chronic PTSD. The company is headquartered in Paris and has US office in Cambridge, MA. MyndBlue’s mission is to change the way mental health conditions are diagnosed through technology, data and design – to get patients the right care. Mental health conditions affect around 615 million people worldwide. MyndBlue’s remote monitoring platform allows for a patient to be monitored with a proprietary device to provide information to a clinician before a crisis.

dsc05102

Michael Quigley, VP of Market Research, Life Science Nation | Denis Fompeyrine, PhD Founder & CEO, Myndblue | Nancy Briefs Serial Medical/Digital Health Entrepreneur, Myndblue | George Ayd Assistant Vice President, Medmarc

Third Place: Propep Surgical (Austin, TX)

propep-surgical-500

Sexual dysfunction and urinary incontinence are both common side effects following prostate cancer surgery. Inadvertent nerve injury occurring during the surgery is believed to be one of the primary causes. Using nerve monitoring technology that has been the Standard of Care in multiple surgical procedures for over 20 years, the ProPep® Nerve Monitoring System brings the same instant and accurate information regarding nerve location and function to laparoscopic and robotic prostatectomy surgery for the first time ever. The ProPep® Nerve Monitoring System is the first FDA-cleared real-time nerve monitoring system for laparoscopic & robotic prostatectomy surgery. With over 2500 commercial cases completed this system is proven to help surgeons identify critical non-visible somatic nerves at risk during surgery, thereby allowing the surgeon to make more-informed decisions on how to spare these nerves, potentially minimizing nerve damage.

Thank you to all who competed in the RESI San Francisco Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

%d bloggers like this: